First Time Loading...

MediciNova Inc
NASDAQ:MNOV

Watchlist Manager
MediciNova Inc Logo
MediciNova Inc
NASDAQ:MNOV
Watchlist
Price: 1.47 USD 8.09% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

MNOV's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. [ Read More ]

The intrinsic value of one MNOV stock under the Base Case scenario is 0.23 USD. Compared to the current market price of 1.47 USD, MediciNova Inc is Overvalued by 84%.

Key Points:
MNOV Intrinsic Value
Base Case
0.23 USD
Overvaluation 84%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MediciNova Inc

Backtest MNOV Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MNOV stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of MediciNova Inc's business.

What risks and challenges
does MediciNova Inc face in the near future?

Summarize the latest earnings report
of MediciNova Inc.

Provide P/E
for MediciNova Inc and its competitors.

Financials

Balance Sheet Decomposition
MediciNova Inc

Current Assets 51.2m
Cash & Short-Term Investments 51m
Other Current Assets 174.9k
Non-Current Assets 15.1m
PP&E 621.2k
Intangibles 14.4m
Other Non-Current Assets 74.2k
Current Liabilities 3.3m
Accounts Payable 1m
Accrued Liabilities 2.3m
Non-Current Liabilities 612.5k
Other Non-Current Liabilities 612.5k
Efficiency

Earnings Waterfall
MediciNova Inc

Revenue
1m USD
Operating Expenses
-10.9m USD
Operating Income
-9.9m USD
Other Expenses
1.3m USD
Net Income
-8.6m USD

Free Cash Flow Analysis
MediciNova Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MNOV Profitability Score
Profitability Due Diligence

MediciNova Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

MediciNova Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

MNOV Solvency Score
Solvency Due Diligence

MediciNova Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
69/100
Solvency
Score

MediciNova Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MNOV Price Targets Summary
MediciNova Inc

There are no price targets for MNOV.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MNOV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MNOV Price
MediciNova Inc

1M 1M
+8%
6M 6M
-31%
1Y 1Y
-32%
3Y 3Y
-69%
5Y 5Y
-82%
10Y 10Y
-29%
Annual Price Range
1.47
52w Low
1.28
52w High
2.6
Price Metrics
Average Annual Return -27.11%
Standard Deviation of Annual Returns 13.53%
Max Drawdown -90%
Shares Statistics
Market Capitalization 72.1m USD
Shares Outstanding 49 050 000
Percentage of Shares Shorted 0.82%

MNOV Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

MediciNova Inc Logo
MediciNova Inc

Country

United States of America

Industry

Biotechnology

Market Cap

72.1m USD

Dividend Yield

0%

Description

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company is headquartered in La Jolla, California and currently employs 11 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. The company is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.

Contact

CALIFORNIA
La Jolla
4275 Executive Sq Ste 300
+18583731500.0
https://medicinova.com/

IPO

2006-12-01

Employees

11

Officers

Co-Founder, President, CEO & Executive Director
Dr. Yuichi Iwaki M.D., Ph.D.
Chief Medical Officer & Director
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.
Chief Business Officer
Dr. David H. Crean M.B.A., Ph.D.
Controller
Mr. John O'Neil CPA

See Also

Discover More
What is the Intrinsic Value of one MNOV stock?

The intrinsic value of one MNOV stock under the Base Case scenario is 0.23 USD.

Is MNOV stock undervalued or overvalued?

Compared to the current market price of 1.47 USD, MediciNova Inc is Overvalued by 84%.